The depth of our bioavailability (BA) enhancement offering makes us a leader in addressing low solubility, low bioavailability and dissolution rate issues. We work collaboratively with our customers to advance compounds, or re-purpose existing compounds, across a full range of API properties and delivery challenges. Our end-to-end enhancement solutions incorporate full capabilities in bringing a compound from concept to commercialization, thereby minimizing program complexity, timelines and risk.

Industry estimates indicate that more than 80% of new chemical entities exhibit low solubility, low bioavailability and / or low or inconsistent dissolution rate. Effectively addressing these drug solubility, bioavailability and dissolution rate problems is essential for advancing the compound and providing the desired therapeutic benefit of the drug product to patient. And ensuring that the solubility solution incorporates the ultimate manufacturability of the drug product can avoid time-consuming re-formulation and ensure rapid advancement to market.

We recognize the core challenges of advancing the new chemical compounds in today’s biopharmaceutical pipeline. That’s why we have developed a portfolio of bioavailability enhancement technologies and services with which to address poor solubility and inadequate or inconsistent dissolution rate.

Our commitment to our customers includes a 30+ year track record across our fit-for-purpose bioavailability enhancement techniques with phase-appropriate processing in place to support non-GMP feasibility assessments through GMP clinical trials and commercial-scale manufacturing.

Want to learn about some of the most common bioavailability enhancing technologies for poorly soluble compounds?

Bioavailability enhancement trends – hear from our experts

Learn more from Deanna and David about continuing innovation in spray-dried dispersion technology.

This webinar focuses on the design of dissolution media to support biopredictive dissolution testing, and highlights a method for selecting practical, physiologically relevant media based upon drug, formulation, and GI fluid properties.

View On-Demand

Streamlined Selection of in vivo Predictive Dissolution Media

Proven bioavailability enhancement technologies

Our bioavailability enhancement technologies include:

  • Particle size reduction: micronization and nano-milling
  • Solid dispersion technologies: hot-melt extrusion or spray drying
  • Specialized nanocrystalline dispersion and spray-dried nanoadsorbate technologies

Complementary drug delivery technologies are utilized to modulate pharmacokinetics of the solubilized compound and achieve a full range of absorption profiles.

Our scientists take a data-driven approach to characterizing BA problem statement(s) and selecting the enabling technology to advance your compound.

Our integrated product design and development services provide the full range of capabilities to support the rapid advancement of compounds from concept to clinic. This range of services has been integrated in our SimpliFiH® Solutions offering designed to be phase-appropriate and to simplify your pathway to IND/IMPD studies:

  • API development and supply
  • API characterization
  • Product design and preformulation development
  • Formulation and product development
  • Analytical services and quality control
  • Clinical trial manufacture
  • Clinical packaging and supply services

Additionally, our SimpliFiH® Solutions integrated service package is designed specifically to rapidly advance compounds to first-in-human studies.

Industry estimates indicate that more than 80% of new chemical entities exhibit poor solubility or dissolution rate.

Have a Question?

David Lyon, Ph.D.

Area of Expertise: Bioavailability Enhancement

Ask David
We have advanced thousands of bioavailability-challenged molecules over a 25+ year history across all enabling technologies

small molecules and intermediates

Bend, OR, USA

Production, Sales & Support, Research & Development

1201 NW Wall St.
Bend, OR 97703
United States of America (the)

Quakertown, PA, USA


20 Pacific Dr.
Quakertown, PA 18951
United States of America (the)

Monteggio, Switzerland

Production, Research & Development, Sales & Support

Via Cantonale 4
Monteggio 6998

related content

KC BAE-filtered content list
Check out all of our bioavailability enhancement related content in the Knowledge Center
Bioavailability Enhancement Technologies
Tech brief
In Vitro Test Methodologies for Characterizing Bioavailability Enhancing Formulations webinar
Webinar on-demand
Science of Scale for Spray-Dried Intermediates